Relapsed, refractory ovarian cancer
Conditions
Interventions
experimental group:MSLN-CAR-T
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Subjects fully understand the significance and risks of this experiment and voluntarily join this study, signing an informed consent; 2. Age and gender: female subjects >= 18 and = 25%); 5. Multi-line standard treatment failure and unsuitable or unwilling to accept other treatments; 6. According to the RECIST standard, there is at least one imaging-evaluable lesion; 7. Expected survival time >= 3 months; 8. ECOG score 0-2 points; 9. WBC >= 2.5 * 10^9 / L, LY >= 0.7 * 10^9 / L, LY% >= 15, Hb >= 90g / L, PLT >= 80 * 10^9 / L; 10. Subjects must meet the following biochemical indicators: total bilirubin = 50%; Blood oxygen saturation 95%-99%.
Exclusion criteria
Exclusion criteria: 1. Subjects are HIV antibody positive, HBV-DNA positive, HCV-RNA positive, and syphilis antibody positive; 2. Uncontrollable coronary artery disease or asthma, uncontrollable cerebrovascular disease; 3. Those with a history of bone marrow or organ transplantation; those with coagulopathy; 4. People with immunodeficiency diseases or autoimmune diseases; those who have graft-versus-host disease (GVHD), or need to use immunosuppressants; 5. Subjects who have undergone the following immunotherapy within 1 month (therapeutic antibody therapy, immune cell therapy, immune system regulator, etc.); 6. Patients who have systematically used excessive doses of glucocorticoids (converted to prednisone dose> 10mg daily) within 1 month; 7. Severe liver and kidney dysfunction; 8. Uncontrolled diabetic patients; 9. Those who may be allergic to immunotherapy; 10. Pregnancy, breastfeeding women and female subjects who plan to become pregnant within 1 year after cell transfusion; 11. Participating or having participated in other clinical trials within 1 month; 12. Any uncertain factors that affect the safety or compliance of the subject; 13. Patients with secondary brain metastasis, untreated; 14. Those with a second tumor; 15. Have a history of mental illness, and the evaluation of the investigator believes that the patient cannot or unwilling to comply with the requirements of the research protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate, ORR;Adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival, PFS;Duration of Response, DoR; | — |
Countries
China
Contacts
Public ContactYi Zhang
Outcome results
None listed